Snake Bite Envenomation in Critical Care: Distinguishing toxicities

 

Snake Bite Envenomation in Critical Care: Distinguishing Neurotoxic and Hemotoxic Syndromes with Focus on Point-of-Care Testing

Dr Neeraj Manikath , claude.ai

Abstract

Background: Snake bite envenomation remains a significant cause of morbidity and mortality globally, with an estimated 81,000-138,000 deaths annually. Critical care physicians must rapidly differentiate between neurotoxic and hemotoxic envenomation patterns to guide appropriate management.

Objective: This review synthesizes current evidence on the pathophysiology, clinical recognition, and management of snake bite envenomation, with particular emphasis on point-of-care coagulation testing in hemotoxic syndromes.

Methods: Comprehensive literature review of peer-reviewed articles, clinical guidelines, and case series published between 2010-2024.

Results: Neurotoxic envenomation presents with descending paralysis and respiratory failure, while hemotoxic envenomation manifests with coagulopathy, bleeding, and potential cardiovascular collapse. Point-of-care testing, particularly the 20-minute whole blood clotting test (20WBCT), provides rapid assessment of coagulation status with high sensitivity for detecting consumptive coagulopathy.

Conclusions: Early recognition of envenomation syndromes and judicious use of antivenom guided by clinical assessment and point-of-care testing can significantly improve outcomes in critically ill patients.

Keywords: Snake bite, envenomation, neurotoxic, hemotoxic, coagulopathy, point-of-care testing, antivenom

---

Introduction

Snake bite envenomation represents one of the most neglected tropical diseases, affecting predominantly rural populations in developing countries. The World Health Organization estimates that venomous snakes cause 81,000-138,000 deaths annually, with three times as many amputations and other permanent disabilities¹. For critical care physicians, snake bite envenomation presents unique challenges requiring rapid assessment, syndrome recognition, and timely intervention.

The clinical presentation of envenomation varies dramatically based on the species involved, with two predominant patterns emerging: neurotoxic and hemotoxic syndromes. Understanding these patterns, their underlying pathophysiology, and the role of point-of-care testing is crucial for optimal patient outcomes.

Epidemiology and Global Burden

Geographic Distribution

• Asia-Pacific: Accounts for approximately 50% of global envenomations, with Russell's viper, cobras, and kraits being predominant
• Sub-Saharan Africa: Saw-scaled vipers, puff adders, and mambas cause significant morbidity
• Americas: Pit vipers (rattlesnakes, copperheads) and coral snakes in North America; Bothrops species in Central and South America
• Australia: Elapids including taipans, brown snakes, and death adders²

High-Risk Populations

• Agricultural workers and farmers (60-70% of cases)
• Children and adolescents (higher case-fatality rates)
• Remote rural populations with limited healthcare access

Venom Composition and Pathophysiology

Neurotoxic Venoms

Mechanism of Action

Neurotoxic venoms primarily contain:

• α-neurotoxins: Postsynaptic nicotinic receptor antagonists
• β-neurotoxins: Presynaptic phospholipases affecting acetylcholine release
• Fasciculins: Acetylcholinesterase inhibitors

Species Examples

• Elapidae family: Cobras (Naja spp.), mambas (Dendroaspis spp.), kraits (Bungarus spp.)
• Sea snakes (Hydrophidae family)
• Australian elapids (Acanthophis, Pseudonaja, Notechis)

Clinical Pearl 💎

The "ptosis-to-paralysis" progression: Neurotoxic envenomation classically presents with bilateral ptosis as the earliest sign, progressing to bulbar paralysis, limb weakness, and ultimately respiratory paralysis. This descending pattern helps differentiate from other causes of acute paralysis.

Hemotoxic Venoms

Mechanism of Action

Hemotoxic venoms contain multiple procoagulant and anticoagulant enzymes:

• Metalloproteinases: Cause hemorrhage through vessel wall destruction
• Hyaluronidases: Enhance venom spread through tissues
• Procoagulant enzymes: Factor V and X activators leading to consumptive coagulopathy
• Anticoagulant compounds: Direct fibrinogen depletion, platelet dysfunction

Species Examples

• Viperidae family: Russell's viper (Daboia russelii), saw-scaled vipers (Echis spp.)
• American pit vipers: Rattlesnakes (Crotalus spp.), copperheads (Agkistrodon spp.)
• Australian elapids with hemotoxic properties: Taipans, some brown snakes³

Clinical Syndromes

Neurotoxic Envenomation

Early Signs (0-6 hours)

• Bilateral ptosis (sensitivity 95% for neurotoxic envenomation)
• Diplopia and blurred vision
• Difficulty swallowing
• Altered voice quality
• Muscle fasciculations at bite site

Progressive Signs (6-12 hours)

• Descending flaccid paralysis
• Bulbar weakness: dysphagia, dysarthria, drooling
• Limb weakness progressing proximally
• Reduced deep tendon reflexes

Late Signs (>12 hours)

• Respiratory paralysis requiring mechanical ventilation
• Complete ophthalmoplegia
• Cardiovascular instability (bradycardia, hypotension)

Clinical Hack 🔧

The "ice pack test": Application of ice to ptotic eyelids may temporarily improve ptosis in myasthenia gravis but has no effect in snake bite-induced ptosis. This simple bedside test can help differentiate between these conditions in the appropriate clinical context.

Hemotoxic Envenomation

Coagulation Disorders

• Consumptive coagulopathy: Most common pattern, resembling DIC
• Anticoagulant effect: Direct fibrinogen consumption and platelet dysfunction
• Hemorrhage: Both local and systemic bleeding

Local Effects

• Progressive swelling extending proximally
• Compartment syndrome risk
• Tissue necrosis and bullae formation
• Secondary infection risk

Systemic Manifestations

• Spontaneous bleeding: epistaxis, hemoptysis, hematuria
• Intracranial hemorrhage (rare but fatal)
• Gastrointestinal bleeding
• Hypotensive shock from blood loss or capillary leak

Oyster Alert ⚠️

Delayed coagulopathy recurrence: Even after initial correction with antivenom, coagulopathy can recur 12-48 hours later due to ongoing venom absorption and shorter antivenom half-life compared to venom elimination. Daily coagulation monitoring for 72 hours is essential.

Point-of-Care Coagulation Testing

20-Minute Whole Blood Clotting Test (20WBCT)

Methodology

1. Collect 2-3 ml of venous blood in a clean, dry glass tube
2. Leave undisturbed for 20 minutes at room temperature
3. Tip tube gently to observe clot formation

Interpretation

• Normal: Firm clot that doesn't break when tube is inverted
• Abnormal: No clot formation or clot breaks when tube is inverted
• Sensitivity: 90-95% for detecting consumptive coagulopathy
• Specificity: 70-80%

Advantages

• No equipment required
• Rapid results (20 minutes)
• High negative predictive value
• Cost-effective for resource-limited settings

Limitations

• Subjective interpretation
• Cannot quantify degree of coagulopathy
• May normalize before other parameters

Alternative Point-of-Care Tests

Thromboelastography (TEG) / Rotational Thromboelastometry (ROTEM)

• Provides comprehensive coagulation assessment
• Expensive and requires specialized training
• Useful in developed healthcare settings

Coagulation Monitors (CoaguChek, etc.)

• Rapid PT/INR measurement
• Limited availability in many endemic areas
• May be unreliable in severe coagulopathy

Clinical Decision Algorithm

Assessment Protocol

1. History and Examination

   • Snake identification (if possible)
   • Time since bite
   • Clinical syndrome recognition

2. Immediate Testing

   • 20WBCT at presentation
   • Repeat every 6 hours for first 24 hours
   • Complete blood count
   • Comprehensive metabolic panel

3. Laboratory Confirmation (when available)

   • Prothrombin time/INR
   • Activated partial thromboplastin time
   • Fibrinogen level
   • D-dimer
   • Platelet count

Management Strategies

Immediate Assessment and Stabilization

Primary Survey

• Airway: Early intubation for bulbar weakness or respiratory distress
• Breathing: Mechanical ventilation may be required for neurotoxic envenomation
• Circulation: IV access, fluid resuscitation, blood pressure monitoring
• Disability: Neurological assessment, Glasgow Coma Scale
• Exposure: Complete examination for bite marks, local effects

Antivenom Therapy

Indications

Neurotoxic Envenomation:

• Any evidence of systemic neurotoxicity
• Progressive paralysis
• Respiratory compromise

Hemotoxic Envenomation:

• Abnormal 20WBCT
• Clinical bleeding
• Rapidly progressive local swelling

Dosing Principles

• Polyvalent antivenoms: Cover multiple local species
• Fixed dosing: Adult dose same as pediatric (venom amount constant)
• IV route preferred: Better bioavailability than IM
• Slow infusion: Reduce anaphylaxis risk

Administration Protocol

1. Premedication: Adrenaline readily available
2. Test dose: Not routinely recommended (delays treatment)
3. Initial dose: As per manufacturer guidelines (typically 5-10 vials)
4. Monitoring: Continuous vital signs, repeat 20WBCT at 6 hours
5. Repeat dosing: If coagulopathy persists or neurological progression continues

Supportive Care

Neurotoxic Envenomation

• Mechanical ventilation: May require prolonged support (days to weeks)
• Anticholinesterases: Limited evidence, may help in some cases
• Nutrition: Early enteral feeding via nasogastric tube
• DVT prophylaxis: Appropriate for paralyzed patients

Hemotoxic Envenomation

• Blood products: FFP, cryoprecipitate, platelets as indicated
• Compartment syndrome: Surgical consultation for fasciotomy
• Wound care: Antiseptic cleaning, tetanus prophylaxis
• Pain management: Avoid aspirin and NSAIDs

Complications and Long-term Outcomes

Acute Complications

Neurotoxic

• Respiratory failure (most common cause of death)
• Aspiration pneumonia
• Cardiovascular collapse
• Rhabdomyolysis (rare)

Hemotoxic

• Hemorrhagic shock
• Acute kidney injury
• Compartment syndrome
• Secondary infection

Long-term Sequelae

• Chronic kidney disease (10-15% of survivors)
• Limb amputation (5% of cases with significant local effects)
• Post-traumatic stress disorder
• Neurocognitive impairment (rare)

Quality Improvement and System Considerations

Healthcare System Preparedness

• Antivenom availability: Regional stockpiling strategies
• Staff training: Recognition and initial management protocols
• Transfer protocols: Criteria for ICU admission and inter-facility transfer

Performance Metrics

• Time to antivenom administration (<6 hours optimal)
• Mortality rates by syndrome type
• Length of stay and resource utilization
• Long-term functional outcomes

Future Directions

Research Priorities

• Development of recombinant antivenoms
• Improved point-of-care diagnostics
• Telemedicine applications for remote areas
• Preventive strategies and community education

Technology Integration

• Mobile apps for snake identification
• Telemedicine consultation networks
• Portable ultrasound for compartment syndrome assessment

Clinical Pearls and Oysters Summary

Pearls 💎

1. Ptosis is the canary in the coal mine for neurotoxic envenomation
2. 20WBCT remains the gold standard point-of-care test in resource-limited settings
3. Fixed antivenom dosing - children need the same dose as adults
4. Early intubation before complete paralysis in neurotoxic cases
5. Daily coagulation monitoring for 72 hours post-antivenom

Oysters ⚠️

1. Normal initial 20WBCT doesn't exclude envenomation (may develop later)
2. Coagulopathy can recur 12-48 hours after initial treatment
3. Local swelling without systemic signs may still require antivenom
4. Tourniquet application can worsen local tissue damage
5. Traditional remedies may delay appropriate treatment

Conclusion

Snake bite envenomation in critical care requires rapid syndrome recognition, appropriate use of point-of-care testing, and timely antivenom administration. The 20-minute whole blood clotting test remains a valuable tool for detecting hemotoxic envenomation in resource-limited settings. Understanding the distinct pathophysiology of neurotoxic versus hemotoxic syndromes enables targeted management strategies that can significantly improve patient outcomes.

Critical care physicians must maintain high clinical suspicion, utilize available point-of-care testing judiciously, and implement systematic approaches to antivenom therapy while providing comprehensive supportive care for both local and systemic effects of envenomation.

---

References

1. Kasturiratne A, Wickremasinghe AR, de Silva N, et al. The global burden of snakebite: a literature analysis and modelling based on regional estimates of envenoming and deaths. PLoS Med. 2008;5(11):e218.

2. Williams DJ, Faiz MA, Abela-Ridder B, et al. Strategy for a globally coordinated response to a priority neglected tropical disease: Snakebite envenoming. PLoS Negl Trop Dis. 2019;13(2):e0007059.

3. Isbister GK, Buckley NA, Page CB, et al. A randomized controlled trial of fresh frozen plasma for coagulopathy in Russell's viper (Daboia russelii) envenoming. J Thromb Haemost. 2013;11(7):1310-1318.

4. Slagboom J, Kool J, Harrison RA, Casewell NR. Haemotoxic snake venoms: their functional activity, impact on snakebite victims and pharmaceutical promise. Br J Haematol. 2017;177(6):947-959.

5. Warrell DA. Snake bite. Lancet. 2010;375(9708):77-88.

6. Isbister GK, Maduwage K, Shahmy S, et al. Diagnostic 20-min whole blood clotting test in Russell's viper envenoming delays antivenom treatment. QJM. 2013;106(10):925-932.

7. Silva A, Maduwage K, Sedgwick M, et al. Neurotoxicity in Russell's viper (Daboia russelii) envenoming in Sri Lanka: a clinical and epidemiological study. Trans R Soc Trop Med Hyg. 2014;108(4):259-265.

8. Berling I, Isbister GK. Hematologic effects and complications of snake envenoming. Transfus Med Rev. 2015;29(2):82-89.

9. Maduwage K, Isbister GK. Current treatment for venom-induced consumption coagulopathy resulting from snakebite. PLoS Negl Trop Dis. 2014;8(10):e3220.

10. World Health Organization. Snakebite envenoming: a strategy for prevention and control. Geneva: WHO Press; 2019.

---

 Conflicts of Interest: None declared Funding: None received